Vivo Bio Tech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Vivo Bio Tech şirketinin kazançları yıllık ortalama -2.2% oranında azalırken, Life Sciences sektörünün kazançları yıllık 25.2% oranında artan oldu. Gelirler yıllık ortalama 2.5% oranında azalan oldu. Vivo Bio Tech şirketinin öz sermaye getirisi 12.5% olup, net marjı 14.5% dir.

Anahtar bilgiler

-2.2%

Kazanç büyüme oranı

-6.6%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	11.2%
Gelir büyüme oranı	-2.5%
Özkaynak getirisi	12.5%
Net Marj	14.5%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Vivo Bio Tech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BSE:511509 Gelir, gider ve kazançlar (INR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	514	75	196
30 Jun 24	440	26	193
31 Mar 24	455	25	202
31 Dec 23	485	39	212
30 Sep 23	491	27	216
30 Jun 23	525	25	236
31 Mar 23	522	26	237
31 Dec 22	528	-1	247
30 Sep 22	522	11	247
30 Jun 22	497	13	258
31 Mar 22	514	22	239
31 Dec 21	522	32	272
30 Sep 21	511	41	259
30 Jun 21	556	59	268
31 Mar 21	518	57	268
31 Dec 20	500	50	247
30 Sep 20	523	40	285
30 Jun 20	512	42	278
31 Mar 20	554	44	321
31 Dec 19	548	19	227
30 Sep 19	551	18	227
30 Jun 19	554	15	227
31 Mar 19	558	22	324
31 Mar 18	470	31	172
31 Mar 17	341	25	181
31 Mar 16	286	9	131
31 Mar 15	178	5	98
31 Mar 14	161	3	99

Kaliteli Kazançlar: 511509 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 511509 'nin mevcut net kar marjları (14.5%) geçen yılın (5.5%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 511509 şirketinin kazançları son 5 yılda yılda 2.2% oranında azaldı.

Büyüme Hızlandırma: 511509 'un son bir yıldaki kazanç büyümesi ( 178% ) 5 yıllık ortalamasını (yıllık -2.2% ) aşıyor.

Kazançlar vs. Sektör: 511509 geçen yılki kazanç büyümesi ( 178% ) Life Sciences sektörünün 37.9% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 511509 'nin Özsermaye Getirisi ( 12.5% ) düşük olarak değerlendiriliyor.

Vivo Bio Tech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2025 earnings released: EPS: ₹3.51 (vs ₹0.22 in 2Q 2024)

Vivo Bio Tech Limited to Report Q2, 2025 Results on Nov 14, 2024

First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.10 in 1Q 2024)

Vivo Bio Tech Limited to Report Q1, 2025 Results on Aug 10, 2024

Full year 2024 earnings released: EPS: ₹1.70 (vs ₹1.79 in FY 2023)

Vivo Bio Tech Limited to Report Q4, 2024 Results on May 20, 2024

Recent updates

Second quarter 2025 earnings released: EPS: ₹3.51 (vs ₹0.22 in 2Q 2024)

Vivo Bio Tech Limited to Report Q2, 2025 Results on Nov 14, 2024

Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.10 in 1Q 2024)

Vivo Bio Tech Limited to Report Q1, 2025 Results on Aug 10, 2024

Full year 2024 earnings released: EPS: ₹1.70 (vs ₹1.79 in FY 2023)

Vivo Bio Tech Limited to Report Q4, 2024 Results on May 20, 2024

Investor sentiment deteriorates as stock falls 15%

Third quarter 2024 earnings released: EPS: ₹0.89 (vs ₹0.10 in 3Q 2023)

Vivo Bio Tech Limited to Report Q3, 2024 Results on Feb 12, 2024

Vivo Bio Tech Limited Appoints Vaishnavi Kiran Ayinampudi as Company Secretary & Compliance Officer

Investor sentiment improves as stock rises 21%

Second quarter 2024 earnings released: EPS: ₹0.22 (vs ₹0.08 in 2Q 2023)

Vivo Bio Tech Limited to Report Q2, 2024 Results on Nov 14, 2023

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2023

Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹0.10 (vs ₹0.22 in 1Q 2023)

Vivo Bio Tech Limited to Report Q1, 2024 Results on Aug 07, 2023

Investor sentiment improves as stock rises 33%

Full year 2023 earnings released: EPS: ₹1.78 (vs ₹1.56 in FY 2022)

Vivo Bio Tech Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹0.10 (vs ₹0.97 in 3Q 2022)

Vivo Bio Tech Limited to Report Q3, 2023 Results on Feb 13, 2023

Vivo Bio Tech Limited announced a financing transaction

Second quarter 2023 earnings released: EPS: ₹0.08 (vs ₹0.20 in 2Q 2022)

Vivo Bio Tech Limited to Report Q2, 2023 Results on Nov 14, 2022

Investor sentiment improved over the past week

Vivo Bio Tech Limited, Annual General Meeting, Sep 28, 2022

First quarter 2023 earnings released: EPS: ₹0.22 (vs ₹0.87 in 1Q 2022)

Vivo Bio Tech Limited to Report Q1, 2023 Results on Aug 10, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.20 (vs ₹1.63 in 2Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹0.87 (vs ₹0.76 in 1Q 2021)

Full year 2021 earnings released: EPS ₹4.23 (vs ₹3.45 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ₹1.73 (vs ₹1.02 in 3Q 2020)

Vivo Bio Tech Limited to Report Q3, 2021 Results on Feb 10, 2021

Investor sentiment improved over the past week

New 90-day high: ₹54.60

Investor sentiment improved over the past week

COO & Head of Business Development recently sold ₹288k worth of stock

New 90-day high: ₹53.40

Vivo Bio Tech Limited to Report Q2, 2021 Results on Nov 11, 2020

Market pulls back on stock over the past week

Market bids up stock over the past week

Market bids up stock over the past week

Market bids up stock over the past week

Vivo Bio Tech Limited announced that it expects to receive INR 81 million in funding

Vivo Bio Tech Limited to Report Q1, 2020 Results on Aug 28, 2020

New 90-day high - ₹32.00

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin